How has been the historical performance of the Transgene Biotek?

Answer:The historical performance of Transgene Biotek shows a gradual increase in net sales over the years, with figures rising from Rs 0.06 crore in March 2023 to Rs 0.26 crore in March 2025. However, the company has consistently reported negative operating profits, with an operating profit of -1.13 crore in March 2025, indicating ongoing financial challenges. The total expenditure has also increased, reaching Rs 1.39 crore in March 2025, which has contributed to the negative profit before tax of -0.68 crore for the same period. The net profit has remained negative as well, with a loss of -0.68 crore in March 2025, reflecting a trend of increasing losses over the years. The company's reserves have significantly declined, showing a negative reserve of -65.74 crore in March 2025. The total liabilities have remained relatively stable around Rs 142 crore, while total assets have slightly decreased to Rs 142.33 crore in March 2024. The cash flow from operating activities has been stagnant, with no cash inflow reported in recent years.

Breakdown:
Transgene Biotek's financial performance indicates a slight improvement in net sales, increasing from Rs 0.06 crore in March 2023 to Rs 0.26 crore in March 2025. Despite this growth in sales, the company has faced persistent losses, with operating profits remaining negative, culminating in an operating profit of -1.13 crore in March 2025. The total expenditure has escalated to Rs 1.39 crore, further exacerbating the financial strain, as evidenced by a profit before tax of -0.68 crore. The net profit has also shown a consistent downward trend, recording a loss of -0.68 crore in March 2025. Reserves have deteriorated significantly, resulting in a negative reserve of -65.74 crore, while total liabilities have hovered around Rs 142 crore, with total assets slightly declining to Rs 142.33 crore in March 2024. The cash flow from operating activities has remained stagnant, indicating ongoing operational challenges.